Press releases - 2020

Domain Therapeutics launches Phase 1-enabling studies on proprietary EP4 receptor antagonist progra...

Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling ...

Domain Therapeutics presents posters at the American Association for Cancer Research Virtual Annual ...

Domain Therapeutics receives development milestone payment from Merck KGaA, Darmstadt, Germany, fo...

Domain Therapeutics acquires Prestwick Chemical and Neurofit to bolster next stage of growth

Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking

Domain Therapeutics secures €6 million ($6.7M) debt financing